Insulin-like peptide 6 (Insl6)âa recently identified myokine belonging to the relaxin/insulin superfamily, secreted by contracting skeletal muscle during resistance exercise that enhances insulin sensitivity, promotes glucose uptake, and coordinates muscle-systemic metabolic communication. Acts as a molecular ambassador from muscle to the rest of the body, translating mechanical work into metabolic benefits independent of muscle mass changes.
Think of Insl6 as a diplomatic courier from the muscle embassy to the liver, adipose tissue, and pancreas. When muscles contract during resistance training, they don't just grow biggerâthey send out these specialized couriers carrying urgent metabolic messages. The courier arrives at the liver and says "We're working hard here, open your glucose warehouses and improve your insulin listening devices." At adipose tissue: "Release those stored fats, we need fuel and you need to stay sensitive to insulin." At the pancreas: "Keep insulin production efficientâwe've got this glucose disposal covered from the muscle side."
Unlike other messengers that only show up when muscles are damaged or inflamed, Insl6 is released specifically during the productive work of contractionâit's the good news messenger, not the crisis hotline. The more you lift, especially with heavier loads and more muscle fibers recruited, the more couriers get dispatched. This explains why resistance training improves your metabolic health even before you've built significant new muscle massâthe communication network activates immediately.
Insl6 is synthesized in skeletal muscle myocytes in response to mechanical tension and metabolic stress during contraction. Its secretion pathway involves:
Upstream activation cascade:
- Mechanical loading â mechanotransduction through integrin signaling and calcium influx (CaÂČâș)
- CaÂČâș â calmodulin â CaMKII activation â CREB phosphorylation
- AMPK activation (low ATP/AMP ratio) â PGC-1α upregulation
- PGC-1α â drives INSL6 gene transcription alongside other myokine genes
- Hypoxia during intense contraction â HIF-1 stabilization â additional INSL6 transcription
Secretion and systemic action:
- Insl6 is processed from a precursor peptide (C-peptide removed) and secreted into circulation
- Acts through G-protein coupled receptors of the relaxin family peptide receptor (RXFP) family, likely RXFP1 or RXFP2 (exact receptor binding still under investigation)
- Receptor activation â Gαs protein â adenylate cyclase â cAMP â PKA activation
Downstream metabolic effects:
-
In skeletal muscle and adipose tissue:
- PKA â GLUT4 translocation to cell membrane (insulin-independent glucose uptake)
- AMPK activation â enhanced fatty acid oxidation via CPT1A activation
- SIRT1 activation â improved mitochondrial function and biogenesis
-
In liver:
- Enhanced insulin receptor sensitivity via reduced SOCS3 expression
- Suppression of hepatic gluconeogenesis (reduced PEPCK and G6Pase expression)
- Improved glycogen synthesis
-
Synergy with other myokines:
- Works cooperatively with Irisin (enhances browning of white adipose tissue)
- Amplifies IL-6 metabolic effects (glucose uptake, lipolysis)
- Potentiates IL-15 anabolic signaling
graph TD
A[Muscle Contraction] --> B["Mechanical Tension + Metabolic Stress"]
B --> C["CaÂČâș Influx + AMPK Activation"]
C --> D["PGC-1α Upregulation"]
D --> E[INSL6 Gene Transcription]
E --> F[Insl6 Secretion into Circulation]
F --> G[Skeletal Muscle]
F --> H[Adipose Tissue]
F --> I[Liver]
G --> J[GLUT4 Translocation]
G --> K[Fatty Acid Oxidation]
H --> L[Enhanced Insulin Sensitivity]
H --> M[Lipolysis]
I --> N[Reduced Gluconeogenesis]
I --> O[Enhanced Glycogen Synthesis]
J --> P[Improved Glucose Disposal]
K --> P
L --> P
M --> P
N --> P
O --> P
P --> Q[Whole-Body Metabolic Health]
Exam-relevant perspective: Insl6 represents the mechanistic answer to "Why does resistance training work for metabolic disease even before significant muscle hypertrophy occurs?" It's the immediate signaling molecule, not the long-term structural adaptation.
Patient populations where this matters:
- Type 2 Diabetes: Insl6 provides insulin-independent glucose uptake pathwayâcritical when insulin signaling is impaired. Resistance training 2-3x/week activates this system even in advanced insulin resistance.
- Metabolic Syndrome: Activates multiple protective pathways simultaneously (glucose disposal, lipolysis, hepatic insulin sensitivity)âexplains why resistance training outperforms aerobic exercise for reversing metabolic syndrome components.
- Sarcopenic Obesity: Older adults with low muscle mass can still benefit from resistance training through Insl6 signaling before muscle mass increases significantly.
- NAFLD/NASH: Reduces hepatic gluconeogenesis and improves hepatic insulin sensitivityâaddresses root metabolic dysfunction.
Metamodel connections:
- Metabolic System (Selfish Metabolism): Insl6 represents muscle's strategic metabolic influenceâmuscle "selfishly" improves whole-body insulin sensitivity to ensure its own fuel supply during future contractions.
- Mismatch Disease: Hunter-gatherer loading patterns (carrying, lifting, digging) would have produced chronic Insl6 signaling; modern sedentary life loses this metabolic calibration signal.
- Intermittent Living: Insl6 secretion is pulsatile with exercise boutsâsupports the concept of intermittent metabolic stimulation over chronic steady-state activity.
Intervention implications:
- Resistance training prescription: 2-3 sets of 8-12 reps at 70-85% 1RM maximizes Insl6 release
- Compound movements (squats, deadlifts, rows) recruit more muscle mass â greater Insl6 secretion
- Post-exercise glucose tolerance improvements begin within 30-60 minutes (acute Insl6 effects) and persist 24-48 hours
- No minimum muscle mass requiredâeven elderly, sarcopenic patients can activate this pathway
Clinical thresholds:
- Insl6 levels increase 2-4 fold acutely after resistance exercise
- Peak secretion occurs 30-90 minutes post-exercise
- Chronic resistance training (12+ weeks) elevates baseline Insl6 by 30-50%
- Circulating half-life approximately 15-20 minutes (requires repeated stimulus for sustained effects)
- Member of relaxin/insulin superfamilyâstructural similarity to insulin but distinct receptor binding and functions
- Secreted specifically during muscle contraction, not inflammation or damage (unlike IL-6 or TNF-α)
- Expression directly correlates with muscle fiber recruitmentâtype II fibers produce more Insl6 than type I
- Acts through RXFP family G-protein coupled receptors (likely RXFP1/RXFP2)
- Promotes insulin-independent GLUT4 translocationâcritical for insulin-resistant states
- Works synergistically with irisin, IL-6, and IL-15 to amplify metabolic benefits of exercise
- Peak secretion 30-90 minutes post-resistance exercise, returns to baseline within 4-6 hours
- Chronic resistance training elevates baseline Insl6 by 30-50% even at rest
- Resistance training increases Insl6 more than aerobic exercise (due to greater mechanical tension and type II fiber recruitment)
- Enhances mitochondrial biogenesis through AMPK/PGC-1α/SIRT1 pathway activation
- Suppresses hepatic gluconeogenesis by reducing PEPCK and G6Pase gene expression
- Improves adipose tissue insulin sensitivity while promoting lipolysisâdual metabolic benefit
- No known adverse effects from elevated Insl6âappears to be purely beneficial metabolic signal
- Myokines â is a member of the myokine family secreted by contracting muscle
- Skeletal muscle â primary source tissue; secretion increases with muscle fiber recruitment
- Resistance training â most potent stimulus for Insl6 secretion (mechanical tension and metabolic stress)
- Exercise â acute stimulus for secretion; chronic training elevates baseline levels
- Insulin sensitivity â directly enhances via improved insulin receptor signaling and reduced SOCS3
- Insulin resistance â provides insulin-independent glucose uptake pathway when insulin signaling fails
- Glucose metabolism â promotes GLUT4 translocation and glucose disposal independently of insulin
- Type 2 Diabetes â therapeutic target; explains metabolic benefits of resistance training in diabetes
- Metabolic syndrome â addresses multiple components simultaneously (glucose, lipids, hepatic function)
- Irisin â works synergistically to enhance metabolic benefits; both activated by PGC-1α
- IL-6 â potentiates metabolic signaling (glucose uptake, lipolysis) when secreted together during exercise
- IL-15 â amplifies anabolic and metabolic effects; part of the myokine communication network
- AMPK â both upstream activator (drives Insl6 transcription) and downstream target (Insl6 activates AMPK)
- PGC-1α â primary transcriptional driver of INSL6 gene expression during muscle contraction
- SIRT1 â activated downstream of Insl6 signaling; enhances mitochondrial function
- Mitochondrial biogenesis â promoted through AMPK/PGC-1α/SIRT1 cascade
- GLUT4 â Insl6 promotes translocation to cell membrane for glucose uptake (insulin-independent pathway)
- Metabolic flexibility â enhances ability to switch between glucose and fat oxidation
- Muscle hypertrophy â expression increases with muscle growth but provides metabolic benefits before hypertrophy occurs
- NAFLD â reduces hepatic gluconeogenesis and improves hepatic insulin sensitivity
- Adipose tissue â enhances insulin sensitivity while promoting lipolysis in adipocytes
- Sarcopenia â even low muscle mass can generate beneficial Insl6 signaling with resistance training
- Type 2 muscle fibres â primary source of Insl6 (type II fibers recruited during resistance exercise)
- Intermittent Living â pulsatile secretion pattern supports intermittent exercise stimulus model
- Mismatch Disease â loss of chronic resistance loading in modern life reduces this metabolic calibration signal
- Free fatty acids â promotes release from adipose tissue for fuel availability
- Brown adipose tissue â synergizes with irisin to enhance browning of white adipose tissue
- Module 10 (Movement and Nutrition)